STOCKS TELEGRAPH

Category: US Stocks

  • Amprius Technologies (AMPX) Stock Jumps On A Strategic Selection

    Amprius Technologies (AMPX) Stock Jumps On A Strategic Selection

    Amprius Technologies, Inc.’s stock (NYSE: AMPX) went up 10.03% to $7.41 as of today’s latest check, after the company’s selection for the 2025 cohort of the Amazon Devices Climate Tech Accelerator.

    Recognition for SiCore Battery Platform

    As part of Amazon’s wider commitment under The Climate Pledge, this program encourages solutions that reduce carbon emissions throughout its device ecosystem and operations in an effort to reach net-zero emissions by 2040.

    After a thorough evaluation procedure that gave equal weight to technological innovation and environmental effect, Amprius Technologies was selected for distinction for the SiCore Battery Platform. Its unique SiCore battery architecture, which offers an energy density up to 80% greater than traditional lithium-ion batteries, is the main reason for this discrepancy.

    This enables longer running times, quicker charging, and reduced weight—all of which are critical features for creating energy-efficient devices and next-generation applications.

    Impact on the Industry and Collaboration with Amazon

    Amprius Technologies will have the chance to collaborate closely with Amazon’s technical and sustainability teams by joining the accelerator. They will also learn how to apply Amazon’s state-of-the-art silicon anode battery technology to a range of use cases, including consumer electronics, industrial devices, and mobility platforms.

    The involvement highlights how important high-performance batteries are to cutting emissions and promoting electrification in important industries including robotics, light electric cars, and aircraft.

    International Growth Through a Strategic Manufacturing Contract

    To further reinforce its development trajectory, Amprius Technologies has recently signed a new contract manufacturing agreement with a reputable battery manufacturer in South Korea. This action complements AMPX’s capital-light approach to increase the manufacturing of SiCore cells and broadens the company’s global production base.

    Amprius Technologies will be able to provide a global clientele reliable supply chain services and quicker delivery by using this partnership. AMPX is at the forefront of innovation and is ideally positioned to significantly contribute to the development of sustainable technologies and global efforts to decrease carbon emissions as the demand for lighter, more energy-dense batteries expands.

  • Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Daré Bioscience, Inc. (NASDAQ: DARE) shares surged by 74.16% to $4.38 as of the last check during morning trading following the release of encouraging interim data from a Phase 3 clinical trial.

    Positive Interim Analysis Supports Efficacy and Safety

    The trial evaluates the contraceptive effectiveness, safety, and acceptability of Ovaprene, DARE’s investigational monthly, hormone-free intravaginal contraceptive. Notably, no FDA-approved products currently exist within this contraceptive category, placing Ovaprene in a potentially groundbreaking position.

    The study’s Data Safety Monitoring Board (DSMB) conducted a planned interim review and recommended that the trial continue without any modifications. The interim analysis revealed that approximately 9% of women using Ovaprene experienced pregnancy—aligned with prior expectations and data from the pre-pivotal postcoital test study. The effectiveness of ovaprene as a hormone-free contraception is well supported by these studies.

    Crucially, during the review, no significant safety issues were brought forward. Vaginal odor was the most frequent product-related adverse event, causing almost 17% of participants to stop the research. Overall tolerability remained acceptable in spite of this, and most women who finished the experiment had a high propensity to use Ovaprene if it were made commercially accessible.

    A New Direction for Women’s Health

    Ovaprene has the potential to address a significant unmet need in the contraceptive market, according to Daré Bioscience, which expressed confidence about these findings. The business sees Ovaprene as a potentially game-changing solution in reproductive health, given the rising desire among American women for hormone-free birth control solutions.

    Commercial Prospects with Bayer and Future Milestones

    Commercial momentum may accelerate if Bayer elects to exercise its exclusive U.S. commercialization rights following trial completion. This decision would involve a $20 million payment to Daré Bioscience.

    In total, Daré Bioscience stands to gain up to $310 million in commercial milestone payments, along with double-digit tiered royalties on net sales. These payments are subject to a minority interest provision under a royalty purchase agreement made in April 2024.

  • Unusual Machines (UMAC) Extends Pre-Market Rally On Executive Leadership News

    Unusual Machines (UMAC) Extends Pre-Market Rally On Executive Leadership News

    Unusual Machines, Inc. (NYSE: UMAC) is continuing its upward momentum in the pre-market session today, climbing 8.63% to $9.44 at last check. This gain follows a 7.28% rise in the prior session, where UMAC shares closed at $8.69, driven by investor optimism around recent leadership appointments aimed at scaling operations and improving execution.

    Tim Manton Joins as Corporate Controller

    Unusual Machines has appointed Tim Manton, CPA, as its new Corporate Controller. Manton has more than 15 years of financial leadership expertise in high-growth and acquisition-focused firms, and he will directly report to CFO Brian Hoff. His background includes reporting, financial systems integration, and M&A, all of which complement Unusual Machines’ focus on operational rigor in its upcoming expansion stage.

    Manton previously supervised finance during a significant strategic purchase while serving as Director of Finance and Accounting at Sony Electronics (formerly KinaTrax). His prior positions at Ultra Electronics and Blue Force Technologies further enhanced his expertise in post-merger integration and ERP conversions, which are critical competencies as UMAC expands its manufacturing presence in the United States.

    Scaling Operations with Strong Financial Backbone

    Manton’s appointment supports the company’s rapid expansion, including a new 17,000-square-foot motor production facility in Orlando, Florida. The facility will focus on high-performance drone motors designed for regulatory compliance and evolving customer demand. UMAC views financial discipline and operational efficiency as fundamental to its domestic growth and strategic manufacturing goals.

    Stacy Wright Elevated to EVP of Revenue

    In a parallel move, Unusual Machines recently promoted Stacy Wright to Executive Vice President of Revenue. Wright, who joined Rotor Riot in 2020 and became its President in 2024, has been instrumental in the company’s growth trajectory. Under her leadership, quarterly revenue exceeded $2 million in Q1 2025—up from $1.7 million in annual revenue when she first joined.

    Wright will now lead the integration of all revenue-related functions—including sales, marketing, fulfillment, and customer experience—across Unusual Machines’ brands such as Rotor Riot, Fat Shark, and Brave Line. A core part of her mandate involves spearheading commercial strategy for the new Orlando facility and guiding market entry into enterprise, defense, and STEM sectors.

  • After-Hour Rally Continues For ZenaTech Following Prototype Reveal

    After-Hour Rally Continues For ZenaTech Following Prototype Reveal

    During Thursday’s after-hours trading session, ZenaTech, Inc. (NASDAQ: ZENA) had yet another spike in its stock price, rising 11.40% to close at $4.69. This increase came after shares ended at $4.21 after an earlier 8.23% advance in normal trading.

    The company’s revelation of a significant technological milestone—its first quantum computing prototype, intended to underpin cutting-edge AI drone solutions—fueled the market’s excitement.

    Breakthrough in Quantum-AI Integration

    ZenaTech has verified that it has created a fundamental framework for quantum computing that can handle and analyze massive datasets quickly. ZenaTech’s AI-powered drone technology has advanced significantly with this prototype.

    The company tested the technology using sophisticated weather predicting algorithms as part of its “Clear Sky” effort, which allowed for real-time data processing from aerial drone sensors. This framework establishes a standard for agile, data-driven decision-making.

    Increasing Use Cases from the Battlefield to the Farm Field

    ZenaTech anticipates that their innovative technology will find extensive commercial and defense uses. By providing detailed, real-time environmental observations, the innovation has the potential to greatly improve precision farming in the agricultural sector.

    In the energy sector, it promises predictive infrastructure inspections, potentially reducing maintenance costs and increasing safety. Defense uses are equally promising, ranging from improved battlefield decision-making to more precise threat detection, reconnaissance, and electronic warfare operations.

    According to the company, it is “building a quantum-intelligent edge where data becomes decisions in an instant,” underlining its vision to redefine both civil and military drone capabilities.

    Clear Sky Project: Toward Safer Weather Predictions

    The company’s Clear Sky project remains a core research initiative under its quantum computing program. The system analyzes vital meteorological parameters including temperature, wind, humidity, barometric pressure, and precipitation—with high accuracy.

    Internal trials using historical open-source data demonstrated a strong correlation with established weather platforms, validating the system’s reliability. Within the next several months, ZenaTech hopes to grow its R&D department from a six-person team to a 25-person unit.

    The company is eyeing to expedite commercialization, reduce operating expenses, and establish itself as a global leader in quantum and next-generation artificial intelligence. By combining AI drones with quantum computing, ZenaTech is improving weather forecasting while also paving the way for safer skies and more intelligent infrastructures.

  • Nurix (NRIX) Stock Jumps In After-Hour Trading Following Q2 Earnings Release

    Nurix (NRIX) Stock Jumps In After-Hour Trading Following Q2 Earnings Release

    Following a 7.94% increase during the regular session, when the stock finished at $13.18, Nurix Therapeutics, Inc. (NASDAQ: NRIX) showed great momentum in the extended trading session, rising 17.37% to $15.47.

    The company’s Q2 2025 financial results, which showed notable revenue growth and milestone accomplishments throughout its medicinal portfolio and partnerships, preceded the strong increase.

    Partnerships Drive Revenue Growth

    Nurix recorded $44.1 million in revenue for the fiscal quarter that concluded on May 31, 2025, a significant rise over the $12.1 million generated during the same period the previous year. A $30 million licensing payment from Sanofi as a result of two license agreements being extended and a $5 million milestone payment from Gilead were primarily responsible for this rise.

    The firm reported a net loss of $43.5 million, or ($0.52) per share, despite the upward sales trend. This was a slight improvement above the $44.5 million loss, or ($0.71) per share, in the previous year.

    Clinical Development and Regulatory Successes

    Several clinical and regulatory developments occurred throughout the quarter. Sanofi extended its license for the STAT6 program after Nurix achieved significant milestones, which resulted in an extra $15 million payment. With this extension, the Sanofi collaboration’s total payouts reached $127 million, with a further $465 million in possible future milestones.

    Gilead and Nurix also said that the FDA has approved the IND application for GS-6791 (NX-0479), a first-of-its-kind oral IRAK4 degrader intended to treat inflammatory and autoimmune disorders.

    Promising Clinical Data and EMA Recognition

    Nurix provided strong Phase 1 data for bexobrutideg (NX-5948) at EHA2025 and ICML-18. These data showed an objective response rate of 80.9% in patients with relapsed or refractory CLL, including a full response in a high-risk case.

    Additionally, bexobrutideg was given orphan drug status (ODD) by the European Medicines Agency (EMA) for lymphoplasmacytic lymphoma, providing strategic regulatory advantages inside the EU.

    Artificial Intelligence-Based Innovation

    At the AACR Annual Meeting, Nurix also demonstrated their DEL-AI platform, which uses a unique DNA-encoded library-based foundation model to speed up the discovery of new binders for challenging medicinal targets.

    Nurix’s growing portfolio of degraders and strategic partnerships highlight the company’s leadership in immunology and cancer therapeutic innovation as it enters a critical phase.

  • Ferrero Interest Sends WK Kellogg (KLG) Higher In After-Hour Trades

    Ferrero Interest Sends WK Kellogg (KLG) Higher In After-Hour Trades

    Following rumors of a possible purchase by Ferrero, the Italian candy behemoth behind brands like Ferrero Rocher and Nutella, WK Kellogg Co. (NYSE: KLG) had a notable after-hours spike, gaining 54.63% to end at $27.06.

    After-Hours Rally Follows Acquisition News

    The Wall Street Journal on Wednesday, revealed that Ferrero is nearing a deal to acquire WK Kellogg (KLG) for approximately $3 billion. In comparison to KLG’s current market valuation of around $1.5 billion, this amount indicates a significant premium.

    Ferrero’s U.S. Expansion Strategy

    With the proposed acquisition, Ferrero would undertake yet another bold move to solidify its position in the US food industry. Under Chairman Giovanni Ferrero’s direction, Ferrero, which has long been recognized for its candies and confections, has been growing.

    The company recently purchased Wells Enterprises, producer of Blue Bunny ice cream, and acquired Nestlé’s U.S. chocolate operations in a $2.8 billion deal. With 15 production and distribution facilities spread across North America and the Caribbean, Ferrero now employs over 5,100 workers in the region.

    Beyond Candy: Strategic Diversification

    The acquisition of WK Kellogg is in line with Ferrero’s overarching plan to expand its business outside confections and solidify its position in the US consumer goods industry. Due in major part to consumer preferences for less expensive breakfast options, WK Kellogg, which separated from the Kellogg Company in 2023, has been struggling with declining revenues and decreased demand.

    The company’s repositioning as an acquisition target is similar to that of its rival, Kellanova, which reached a $36 billion agreement with Snickers manufacturer Mars last year.

    Health Scrutiny and Reformulation Efforts

    Amid mounting criticism over the use of artificial dyes in some of its cereals, WK Kellogg has taken steps to address regulatory concerns. KLG recently held discussions with Health Secretary Robert F. Kennedy Jr. and announced plans to reformulate school-served products to eliminate artificial food coloring.

    If the Ferrero deal materializes, shareholders would receive an estimated $27.61 per share, net of $570 million in debt—a potential windfall in a rapidly consolidating food sector.

  • BioSig (BSGM) Advance In Pre-Hour Session After Announcing Tokenization Strategy

    BioSig (BSGM) Advance In Pre-Hour Session After Announcing Tokenization Strategy

    BioSig Technologies, Inc. (NASDAQ: BSGM) shares extended their upward trajectory in pre-market trading, reflecting growing investor optimism. As of the latest pre-market check, BSGM stock had climbed 27.53% to $14.73, building on the prior session’s 1.95% gain that closed at $11.55. The sharp uptick follows news of a definitive agreement aimed at strengthening BioSig’s treasury strategy and initiating a major push into asset tokenization.

    Landmark Financing and Gold Treasury Strategy

    BioSig has finalized arrangements with a major institutional investor for expansion financing of up to $1.1 billion after its recent merger with Streamex Exchange Corporation.

    This calculated action puts the business in a position to rank among the Nasdaq’s biggest gold bullion holdings. The project backs BioSig’s goal of using the tokenization of real-world assets (RWAs) to transform global finance, especially in the $142 trillion commodities industry.

    Sale of Debentures and Equity Credit Line

    A $1 billion Equity Line of Credit and $100 million in senior secured convertible debentures are being sold as part of the arrangement. The debentures have an interest rate of 4% per year, which rises to 18% in the case of default until it is addressed, maturing 24 months after the issuance.

    Priced at 96% of their principal value, the debentures are convertible into BioSig’s common stock and secured by a first-priority lien on select assets. Additionally, BioSig retains the right to draw on the equity line over a 36-month period. A resale registration statement will be filed with the SEC to cover shares issued under these agreements.

    Advancing Tokenization and Blockchain Integration

    With this deal, BioSig intends to cement its identity as a gold-backed treasury company while deepening its investment in blockchain-powered RWA tokenization. The tokenization of tangible goods, particularly gold, is seen by Streamex as a revolutionary development that might have an even greater impact than Bitcoin.

    As per the World Gold Council, daily trading volume in gold bullion stands at $233 billion, over four times that of Bitcoin, underscoring gold’s primacy in the financial ecosystem. This financing is poised to give BioSig strategic flexibility and enhance its influence in both traditional and digital asset markets.

  • Theratechnologies (THTX) Stock Spikes In Pre-Market After Takeover News

    Theratechnologies (THTX) Stock Spikes In Pre-Market After Takeover News

    Shares of Theratechnologies Inc. (NASDAQ: THTX) jumped 32.63% to $3.13 during the pre-hour session after the announcement of a definitive purchase agreement. Following THTX’s signing of a deal with CB Biotechnology, LLC, a division of Future Pak, LLC, a renowned private contract manufacturer, distributor, and packager in the pharmaceutical and nutraceutical sectors, the stock price increased.

    Important Acquisition Information and Appraisal

    In addition to one contingent value right (CVR) per share, the buyer will pay $3.01 in cash for all issued and outstanding common shares of Theratechnologies. Each CVR allows for further aggregate payments of up to $1.19 per share, raising the potential transaction value to $254 million, provided that specific commercial or regulatory milestones are reached.

    The cash offer alone is a 90% premium over Theratechnologies’ 30-day volume-weighted average and a 126% premium over the closing price on April 10, 2025, the day before Future Pak’s first non-binding proposal. When including the CVR, the premium escalates to 216% and 165% over the same metrics, respectively.

    Strategic Process and Shareholder Value

    This acquisition stems from a previously disclosed sale process overseen by a special committee of independent directors. The process was structured to maximize shareholder value. The interest from Future Pak signals strong confidence in Theratechnologies’ innovation pipeline and market potential. The strategic move is also expected to bolster Future Pak’s growth trajectory and broaden patient access through an expanded therapeutic portfolio.

    Closing Timeline and Post-Transaction Outlook

    The transaction is to be executed via a statutory plan of arrangement under Québec’s Business Corporations Act and is slated to close in the fourth quarter of fiscal 2025, pending shareholder and court approvals. Funding will be supported by a $220 million debt facility in addition to cash reserves.

    Upon closing, Theratechnologies (THTX) will transition to a private entity, delist from both the Nasdaq and Toronto Stock Exchange, and cease to be a reporting issuer in Canada and the U.S.

  • Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    During today’s pre-market session, shares of Bone Biologics Corporation (NASDAQ: BBLG) were showing a notable upward trend, rising 82.21% to $7.58 as of the last check. Significant business activities, including a significant patent application and an update on Nasdaq compliance, preceded the notable increase in BBLG’s stock value.

    A Patent Application Promotes Bone Treatment Innovation

    Bone Biologics (BBLG) has submitted a new patent application to the USPTO for its innovative NELL-1 protein technology. The application focuses on the potential therapeutic applications of recombinant human NELL-1 (rhNELL-1) polypeptide compositions to treat a variety of bone-related conditions.

    This scientific discovery represents a major turning point in Bone Biologics’ ongoing attempts to develop more potent treatments, particularly for patients having spinal fusion procedures. If granted, the patent will bolster BBLG’s intellectual property assets and long-term clinical development trajectory.

    Nasdaq Compliance Has Been Restored

    In a different statement, Bone Biologics stated that it is now in compliance with Listing Rule 5550(a)(2), which requires a minimum bid price, as required by the Nasdaq. The Nasdaq Stock Market LLC previously notified the business that its common stock now satisfies all requirements for continuing listing on the Nasdaq Capital Market.

    On April 7, 2025, Nasdaq first informed Bone Biologics that the firm was noncompliant after its shares had fallen below $1.00 per share for 30 straight working days. In order to fix this, BBLG has to keep the closing bid price at least $1.00 for ten consecutive trading sessions, a milestone Bone Biologics officially attained on June 24, 2025.

    Strategic Momentum and Investor Confidence

    Complete listing compliance and a possible patent filing are two events that show Bone Biologics’ strategic goals have advanced significantly. BBLG is positioned well within the biomedical innovation environment thanks to the notable stock rise, which reflects rising investor confidence in the company’s pipeline and operational prospects.

  • After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    After-Market Momentum: INmune Bio (INMB) Shares Leap On Clinical Trial News

    During extended trading hours, INmune Bio, Inc. (NASDAQ: INMB) had a notable spike, with its shares rising 83.28% to $11.51. This upswing followed a regular session decline of 14.79%, where INMB stock closed at $6.28. Following the company’s release of impending findings from its Phase 2 MINDFuL clinical study, which targets early Alzheimer’s Disease (AD), a significant milestone in its research pipeline, there was turbulence.

    Upcoming Conference Call and Trial Overview

    On Monday, June 30, INmune Bio (INMB) will have a conference call to provide the top-line results of the Phase 2 MINDFuL study, which assesses the effectiveness of its experimental medication, XPro, in treating individuals with early-stage Alzheimer’s disease. INmune Bio showcased baseline data and participant biomarker profiles at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna earlier this year, where it revealed first findings.

    With an average participant age of 72, the MINDFuL experiment is a blinded, randomized research that includes people with moderate AD or mild cognitive impairment (MCI). Over the course of 23 weeks, subjects were randomized in a 2:1 ratio to receive weekly subcutaneous injections of either 1.0 mg/kg of XPro or a placebo.

    Trial Endpoints and Patient Characteristics

    The primary endpoint of the trial is the change in cognitive performance using the Early and Mild Alzheimer’s Cognitive Composite (EMACC), a tool specifically designed for early-stage AD trials. EMACC scores at baseline were higher in MCI patients and strongly correlated with other validated scales like MMSE and CDR-SB. Notably, 69.2% of participants were APOE ε4 carriers, and 64.4% met inclusion criteria for more than one inflammatory biomarker.

    Secondary Measures and Future Updates

    Secondary outcomes include assessments using CDR-SB, E-Cog, ADL, the Neuropsychiatric Inventory (NPI), blood-based biomarkers, and neuroimaging. The patient cohort showed remarkable similarity to those in successful Phase III studies. INmune Bio (INMB) had previously indicated plans to release topline MINDFuL trial results by June, a catalyst that has now ignited renewed investor interest in its shares.